Crosstalk between Inflammation and Atherosclerosis in Rheumatoid Arthritis and Systemic Lupus Erythematosus: Is There...

Area of Science:

• Immunology
• Cardiovascular Medicine
• Rheumatology

Background:

• Cardiovascular disease (CVD) is a major cause of death in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
• Traditional CVD risk factors do not fully account for the high incidence of early-onset CVD in these autoimmune diseases.
• Atherosclerosis pathogenesis is increasingly understood as an inflammation-centric process.

Purpose of the Study:

• To review the pathogenesis of atherosclerosis in RA and SLE.
• To highlight RA and SLE as models for chronic inflammation's impact on cardiovascular health.
• To explore immune system involvement in atherosclerosis within these diseases.

Main Methods:

• Review of current literature on atherosclerosis in RA and SLE.
• Examination of the roles of inflammasomes, immune cells (neutrophils, macrophages, lymphocytes), and inflammatory mediators.
• Investigation of autoantigens (e.g., oxidized LDL) and autoantibodies (e.g., anti-beta2-glycoprotein I) in disease progression.

Main Results:

• Chronic inflammation, mediated by immune cells and cytokines, is central to atherosclerosis in RA and SLE.
• Specific immune pathways and autoantibodies contribute significantly to cardiovascular risk.
• The inflammatory milieu in RA and SLE accelerates atherosclerotic plaque development.

Conclusions:

• Atherosclerosis in RA and SLE is driven by chronic systemic inflammation.
• Targeting inflammatory pathways offers potential therapeutic strategies for cardiovascular risk reduction in these patients.
• Understanding immune-mediated mechanisms is crucial for managing CVD in autoimmune diseases.